DISCOVERY BIOLOGY & PHARMACOLOGY SERVICES

• Cytotoxicity and proliferation assays: MTT/XTT/SRB/Cell-titer Glo/ Almar Blue/BrDU/Calcein-AM; 3 D cell culture; cell cycle analysis; microtubule and mitosis test
• Angiogenesis assays: endothelial cell (EC) proliferation, adhesion, migration, invasion, chemotaxis, tubule formation, aorta ring explant, VEGFR signaling
• Epigenetics assays: Acetyltransferase, DNA Methyltransferase, HDAC, Histone Demethylase, Histone Methyltransferase, Bromodomain, PARP screening and profiling 
• Cell free assays: various kinase, phosphatase, and other enzymatic assays 
• Reporter gene assays 
• Analysis of post-translational modification of protein
• Screening of anti-aging agents for cosmetics

• Biomarker validation and measurement using SimpleWestern
• Characterization of mechanism of action of novel drugs
• Target identification and validation of drug candidates and novel compounds
• Drug combination screening for synergistic studies
• Development of companion diagnostic methods
• Simultaneous multiplex analysis gene and protein expression. 

Based upon our decades of expertise of discovery of immunomodulatory drugs (IMiDs), we help:

• Identify and characterize new, potent, and selective ligands that bind and reprogram E3 ligase substrate specificity with our ligand binding assay.
• Develop, characterize, and validate the warhead end of novel PROTACs.
• Enable sensitive quantitation of PROTAC-mediated degradation of targets for DC50 and Dmax values 
• Evaluate the impact of target degraders on efficacy and safety-related translational biomarkers with our automatic western blot, IHC and other platforms.
• Characterize PROTAC selectivity across the proteome and provide a global readout on changes in protein expression using protein microarray such as RPPA.
• Provide on-shelf assays, such as CRBN, BET-VHL binding assay,   VHL and CRBN ternary complex formation assay

•  Cell adhesion, migration, chemotaxis and wound healing 

•  Genome-wide gene array, low density gene array, real-time RT-PCR 

• 3-D anti-psoriatic drug screening 
• 3-D cancer cell viability assay  
• 3-D spheroid cell invasion assay
• 3-D tumor micro-tissue assay
• 3-D anti-skin aging cosmetic ingredient screening

•  Mouse tumor models using patient cancer cells or cell lines (PDX or xenograft models) 
• Angiogenesis models using mice and zebra-fish
• Microbiopsy sampling and real-time monitoring efficacy and toxicity of drugs

• Topical arachidonic acid-induced inflammation model (rodent)
• Adjuvant-induced rheumatoid arthritis model (rodent  AIA)
• Collagen-induced arthritis models (CIA)
• Experimental Autoimmune Encephalomyelitis model (rodent EAE)
• OVA-induced asthma rodent model
• Pristane-Induced Systemic Lupus Erythematosus model (mouse SLE)
• MRL/lpr genetic Systemic Lupus Erythematosus model (mouse SLE)
• Inflammatory Bowel Disease models (rodent IBD)
• Delayed-Type Hypersensitivity model (rodent DTH)
• FITC Induced Dermatitis mouse model
• Imiquimod-induced Psoriasis model
• Bleomycin-induced Pulmonary Fibrosis mouse model

• Analysis of DNA damage (comet, DNA fiber assay), DNA oxidation; DNA methylation 
• Ames test (bacterial reverse mutation, 2 or 5 strains
• Micronucleus test (MNT)
• Mitochondrial toxicity
• CFU assay for hematotoxicity assessment
• Colony-forming cell-fibroblast (CFU-F) assay for mesenchymal toxicity assessment
• Cell-specific cytotoxicity